OnCo
ideasIdea

Qualify one iPSC master cell bank once for many off-the-shelf cell products

Cell therapies made from a single stem cell line could be produced in bulk. Regulators should let companies certify the parent cell line once rather than repeating it for every product.

Induced pluripotent stem cell-derived CAR-NK and CAR-T products (Fate, Century, Sana, Shoreline and others) start from a clonal, gene-edited master cell bank that can in principle yield thousands of doses per run. Today each product's regulatory file repeats the characterisation of the bank (genomic stability, tumourigenicity, identity, adventitious agents). The proposal is a 'qualified master bank' status: a hypoimmune-edited iPSC bank characterised once to an agreed standard and cross-referenced by any product derived from it, with only the differentiation and CAR-specific data submitted per product.

Hypothesis
Qualified-bank status cuts the CMC section of an iPSC-derived product IND by at least half and the time from candidate selection to first-in-human by a year, while enabling a cost of goods per dose below $5,000 at scale.
Rationale
Drug master files for excipients and platform designations for vectors already allow shared, referenced qualification. iPSC banks are the most expensive, most repeated component of the allogeneic pipeline and their characterisation is product-independent.
What would test it
FDA and EMA pilot a master-bank designation with two or three developers, publish the characterisation standard, and compare CMC review questions and timelines against conventional iPSC product INDs.
Maturity
early clinical
Who has to act
regulator
Cost to try
Medium ($1M to $50M)
Years to first evidence
4
Bottlenecks it attacks

Connected

5top

Pages like this

not linked directly; found by shared links

technologies

2
Allogeneic (off-the-shelf) cell therapyCAR-NK & CAR-macrophage

companies

2
Fate TherapeuticsSana Biotechnology

bottlenecks

1
Manufacturing cost and time for living and radioactive medicines